ARTA
MCRB icon

A.R.T. Advisors’s Seres Therapeutics MCRB Stock Holding History

A.R.T. Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-991
Closed -$64K – 1598
2019
Q2 		$64K Buy
+991
New +$94.1K ﹤0.01% 1233
2018
Q2 		– Sell
-2,298
Closed -$337K – 1630
2018
Q1 		$337K Buy
2,298
+1,346
+141% +$258K 0.01% 1097
2017
Q4 		$193K Sell
952
-325
-25% -$66.8K 0.01% 1177
2017
Q3 		$409K Buy
+1,277
New +$349K 0.02% 893
2017
Q2 		– Sell
-588
Closed -$132K – 1591
2017
Q1 		$132K Buy
+588
New +$119K 0.01% 1238

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

A.R.T. Advisors's MCRB Position: Q3 2019 in Review

A.R.T. Advisors sold out of Seres Therapeutics (MCRB) in Q3 2019, closing a stake of 991 shares — an estimated $64K sold.

A.R.T. Advisors first reported a position in MCRB in Q1 2017 and held it in 5 quarters. The position peaked at $409K in Q3 2017. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2019.

  • A.R.T. Advisors reported no remaining Seres Therapeutics position as of Q3 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 991 Seres Therapeutics shares in Q3 2019, an estimated $64K.
  • A.R.T. Advisors first reported a position in Seres Therapeutics in Q1 2017 and held it in 5 quarters.
  • A.R.T. Advisors's Seres Therapeutics position peaked at $409K in Q3 2017.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.